Last reviewed · How we verify
Toragesic® — Competitive Intelligence Brief
phase 3
NSAID
COX-2
Pain management
Small molecule
Live · refreshed every 30 min
Target snapshot
Toragesic® (Toragesic®) — Apsen Farmaceutica S.A.. Toragesic is a nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting prostaglandin synthesis.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Toragesic® TARGET | Toragesic® | Apsen Farmaceutica S.A. | phase 3 | NSAID | COX-2 | |
| Celebrex | celecoxib | Pfizer Inc. (originally Searle/Pharmacia) | marketed | Nonsteroidal Anti-inflammatory Drug [EPC] | COX-2 | 1998-12-31 |
| Cytotec | Misoprostol | Pfizer | marketed | NSAID combined with prostaglandin analog | Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors | 1988-01-01 |
| Etoricoxib (Arcoxia) | Etoricoxib (Arcoxia) | Radboud University Medical Center | marketed | Selective COX-2 inhibitor (coxib) | COX-2 (Cyclooxygenase-2) | |
| ASA | ASA | Biogen | marketed | Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent | Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2) | |
| Ropivacaine Ketorolac | Ropivacaine Ketorolac | University of Aarhus | marketed | Local anesthetic + NSAID combination | Voltage-gated sodium channels (ropivacaine); COX-1/COX-2 (ketorolac) | |
| hydrochloride hydromorphone + flurbiprofen axetil | hydrochloride hydromorphone + flurbiprofen axetil | First Affiliated Hospital, Sun Yat-Sen University | marketed | Opioid analgesic + NSAID combination | Mu-opioid receptor (hydromorphone); COX-1/COX-2 (flurbiprofen axetil) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Celebrex · 10722456 · Formulation · US
- — Celebrex · 10799517 · Formulation · US
- — Celebrex · 9949990 · Formulation · US
- — Celebrex · 9795620 · Formulation · US
- — Celebrex · 9572819 · Formulation · US
- — Celebrex · 10376527 · Formulation · US
Sponsor landscape (NSAID class)
- Antibe Therapeutics Inc. · 3 drugs in this class
- Iroko Pharmaceuticals, LLC · 3 drugs in this class
- Organon and Co · 2 drugs in this class
- Apsen Farmaceutica S.A. · 2 drugs in this class
- Amneal Pharmaceuticals, LLC · 2 drugs in this class
- Behar, Caren, M.D. · 2 drugs in this class
- IDEA AG · 2 drugs in this class
- Noven Pharmaceuticals, Inc. · 2 drugs in this class
- HALEON · 2 drugs in this class
- Pfizer · 2 drugs in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Toragesic® CI watch — RSS
- Toragesic® CI watch — Atom
- Toragesic® CI watch — JSON
- Toragesic® alone — RSS
- Whole NSAID class — RSS
Cite this brief
Drug Landscape (2026). Toragesic® — Competitive Intelligence Brief. https://druglandscape.com/ci/toragesic. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab